SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

SPARC Blocking Peptide

Background

SPARC is a key factor in cell-matrix interactions and possibly tumour aggressiveness. The SPARC gene, which encodes a multifunctional glycoprotein with roles in tissue development, remodelling and fibrosis. A regulator of cell-extracellular matrix (ECM) interactions, SPARC represents a major factor in the ECM remodelling occurring during tumour invasion. *in silico* analysis reveals 4 UTR-SNPs located in the 3′-UTR of the SPARC gene, corresponding to 1474 g a, 1551 g c, 1922 t g and 2072 c t changes, which are significantly associated with tumoral state of the tissue. Of all hits, the 2072 SPARC polymorphism had the best association with cancer.

SPARC therefore is a gene involved in a number of diseases including rheumatoid arthritis, scleroderma, tumor development and metastasis. SPARC variants have been detected in tumour samples of patients with acute myeloblastic leukemia (AML).

Ordering Information

Catalog Number
X1855B

Size
50 µg

Customer Storage
Product should be stored at -20ºC. Aliquot to avoid freeze/thaw cycles

Formulation
Provided as solution in phosphate buffered saline with 0.08% sodium azide

Ship Conditions
Ship at ambient temperature, freeze upon arrival

Stability
Products are stable for one year from purchase when stored properly

Comments

Blocking peptide for use with SPARC antibodies (Cat. Nos. X1860P & X1867P).

Instructions

Incubate antibody neat with at least a 50 fold stoichiometric excess of blocking peptide at 37 deg C for 20 minutes (molecular weights of peptide and antibody are ~2.5 kDa and ~160 kDa, respectively). Antibody can then be diluted to a concentration suitable for Western blot.

Example: 10 µl or 10 µg of Exalpha's rabbit anti-SPARC (Cat. No. X1860P or X1867P) is added to 10 µg of blocking peptide for a total volume of 20 µl. The mixture is allowed to incubate for 20 minutes at 37 deg C prior to dilution in suitable buffer (for Western blot, etc.).

Exalpha Biologicals, Inc. 2 Shaker Road, Bldg. B101 Shirley, MA 01464
Tel: 800.395.1137 Fax: 866.924.5100 www.exalpha.com info@exalpha.com